Consequences of glycan truncation on Fc structural integrity.
Effective characterization of protein-based therapeutic candidates such as monoclonal antibodies (mAbs) is important to facilitate their successful progression from early discovery and development stages to marketing approval. One challenge relevant to biopharmaceutical development is, understanding how the stability of a protein is affected by the presence of an attached oligosaccharide, termed a glycan. To explore the utility of molecular dynamics simulations as a complementary technique to currently available experimental methods, the Fc fragment was employed as a model system to improve our understanding of protein stabilization by glycan attachment. Long molecular dynamics simulations were performed on three Fc glycoform variants modeled using the crystal structure of a human IgG1 mAb. Two of these three glycoform variants have their glycan carbohydrates partially or completely removed. Structural differences among the glycoform variants during simulations suggest that glycan truncation and/or removal can cause quaternary structural deformation of the Fc as a result of the loss or disruption of a significant number of inter-glycan contacts that are not formed in the human IgG1 crystal structure, but do form during simulations described here. Glycan truncation/removal can also increase the tertiary structural deformation of CH2 domains, demonstrating the importance of specific carbohydrates toward stabilizing individual CH2 domains. At elevated temperatures, glycan truncation can also differentially affect structural deformation in locations (Helix-1 and Helix-2) that are far from the oligosaccharide attachment point. Deformation of these helices, which form part of the FcRn, could affect binding if these regions are unable to refold after temperature normalization. During elevated temperature simulations of the deglycosylated variant, CH2 domains collapsed onto CH3 domains. Observations from these glycan truncation/removal simulations have improved our understanding on how glycan composition can affect mAb stability.
Pharmaceutical Research and Development; Biotherapeutics Pharmaceutical Sciences; Pfizer Inc.; Chesterfield, MO USA.
Patrick M
PM
Buck
Pharmaceutical Research and Development; Biotherapeutics Pharmaceutical Sciences; Pfizer Inc.; Chesterfield, MO USA.
Sandeep
S
Kumar
Pharmaceutical Research and Development; Biotherapeutics Pharmaceutical Sciences; Pfizer Inc.; Chesterfield, MO USA.
Satish K
SK
Singh
D018360:Crystallography, X-Ray; D030562:Databases, Protein; D006031:Glycosylation; D006358:Hot Temperature; D006801:Humans; D007141:Immunoglobulin Fc Fragments / Q000737:chemistry* / Q000378:metabolism*; D008954:Models, Biological; D056004:Molecular Dynamics Simulation; D011134:Polysaccharides / Q000737:chemistry*; D014867:Water / Q000737:chemistry
D007141:Immunoglobulin Fc Fragments; D011134:Polysaccharides; D014867:Water
Fc; glycans; glycosylation; molecular dynamics; monoclonal antibodies; oligosaccharides; stability